Business Wire

Enry's Island S.p.A. Becomes the First and Only Venture Builder in the World Listed on a Stock Exchange, After a €20M Round A

27.7.2023 20:46:00 EEST | Business Wire | Press release

Share

Enry's Island S.p.A. is pleased to announce that it has successfully finalised its listing on the Vienna Stock Exchange - MTF, supported by PwC Austria, becoming the first and only Venture Builder in the world listed on a Stock Exchange.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727222549/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Luigi Valerio Rinaldi Founder & Chairman of Enry's Island S.p.A. (Graphic: Business Wire)

“We are really proud of this incredible milestone,” says Luigi Valerio Rinaldi, Chairman & CEO of Enry's Island, “made possible thanks to the trust of internationally qualified operators, such as PwC Austria, supporting us in the Financial Due Diligence and Valuation phase, to successfully finalise the listing process on the Vienna Stock Exchange.

The listing on the VSE consolidates the internationality of the equity story and the scale-up phase of Enry's Island, one of the most interesting and innovative ecosystems on the global VC scene, explained by the following highlights:

  • a distributed corporate architecture, which includes Enry’s Island and its 5 Local Companies (distributed in UK, US, Africa, Italy), with an average of 30 Companies (including portfolio startups).
  • a unique holistic 3-layered framework, made of:
    • Business Layer: Enry's Model™ patented methodology, which later became the subject of economics manuals published by McGraw-Hill
    • Software Layer: HUI.land, a Super-App Saas used by each of the companies and stakeholders of the ecosystem, through which to manage every business function and process in the entire dealflow (from origination to fundraising)
    • Space Layer: Rinascimento5, the first phygital distributed coworking in the world, through which the community of Enry's Island can operate fully remotely;
  • an incredible growth in the quantity and quality of its economic, financial and equity indicators (increase in turnover of x2 in 2022 compared to 2021, which also continues in the first half of 2023, in which the turnover of 2022 has already been reached)
  • a large trust of qualified international investors, such as LDA Capital, a Los Angeles based fund with $11B in portfolio, which closed a €20M A Round with Enry's Island;
  • a success rate of its portfolio companies of 95% against the market average of 5%;
  • one of the first operators (not only among venture builders) to build its own headquarters in the metaverse, as early as 2021 and to have organised phygital investor days in the metaverse.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor relations:
emmanuelle.deba@enrysisland.com
0039 393 9774542

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye